Prostate News and Research

RSS

Facts and treatment options for endometriosis

One out of every two women struggling to conceive may suffer from endometriosis - the leading cause of infertility - according to research from Camran Nezhat, M.D., gynecologist at El Camino Hospital, the hospital of the Silicon Valley.

31 Mar 2010

Virginia Tech professor receives NSF CAREER award for research on cancer therapies using nanotechnology

Preliminary research on cancer treatments using nanotechnology and laser therapy has led to a National Science Foundation (NSF) Faculty Early Career Development (CAREER) award for Marissa Nichole Rylander, Virginia Tech assistant professor jointly appointed in the Department of Mechanical Engineering and Virginia Tech - Wake Forest University School of Biomedical Engineering and Sciences (SBES).

30 Mar 2010

'Because Life is for Living' campaign launched to raise awareness about brachytherapy

Former England Rugby World Cup winner Matt Dawson today launched the 'Because Life is for Living' campaign to raise awareness about brachytherapy, a very precise and highly effective form of radiotherapy to treat cancer.

30 Mar 2010

U.Va. develops Prostate Exam Simulator

Early detection through physical examination is one of the key factors in successfully treating prostate cancer.

30 Mar 2010

Mutations in gene protecting body leads to development of cancer

An important gene that normally protects the body against cancer can itself cause a variety of cancers depending on the specific mutation that damages it, according to a new study by investigators at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James).

30 Mar 2010

GSK re-submits sNDA for Avodart to FDA

GlaxoSmithKline announced today that it has re-submitted the supplemental New Drug Application for Avodart® (dutasteride) for prostate cancer risk reduction among men at increased risk of developing the disease to the US Food and Drug Administration.

30 Mar 2010

Conference on the actions of Vitamin D on human health

An important conference on the actions of Vitamin D on human health is being hosted by Barts and The London Medical School and the MRC Asthma UK Centre in Allergic Mechanisms of Asthma.

30 Mar 2010

Inovio Biomedical's total revenue increased to $2.6M for quarter ended December 31, 2009

Inovio Biomedical Corporation today reported financial results for the quarter and year ended December 31, 2009.

29 Mar 2010

New scientific discoveries show that Canadian maple syrup can be good for health

The Federation of Quebec Maple Syrup Producers is pleased to report on two new scientific discoveries which show that Canadian maple syrup can be good for you. These studies build on recent findings on the nutritional value of maple products, which have revealed both the antioxidant properties of maple syrup as well as the discovery of substantial quantities of abscisic acid.

27 Mar 2010

Agent Orange exposure: VA adds three new illnesses to list of health problems

Well over 100,000 Veterans exposed to herbicides while serving in Vietnam and other areas will have an easier path to qualify for disability pay under a proposed regulation published by the Department of Veterans Affairs (VA) that adds three new illnesses to the list of health problems found to be related to Agent Orange and other herbicide exposures.

27 Mar 2010

Research Roundup: Middle class health cost burden, disparities and cancer, summary of new health law

The Growing Financial Burden Of Health Care: National And State Trends, 2001-2006 - This paper examines the ratio of total out-of-pocket spending for health care and insurance to total family income, using data from the Medical Expenditure Panel Surveys for 2001-2006.

26 Mar 2010

AVASTIN receives Health Canada approval for patients with GBM

Roche Canada announced today that Health Canada has approved AVASTIN(R) (bevacizumab), as a single agent, for the treatment of patients with glioblastoma multiforme, the most aggressive primary malignant brain tumour, after relapse or disease progression, following prior therapy.

26 Mar 2010

Hybridyne Imaging Technologies – Brookhaven National Lab team vies for top title at 2010 WBT showcase

A team from Hybridyne Imaging Technologies, Inc., and the U.S. Department of Energy's Brookhaven National Laboratory was among over 90 top technology innovators from across the nation and around the world competing in Arlington, Texas, March 16-17, for top honors at the WBT2010 showcase presented by Lockheed Martin.

25 Mar 2010

Beaumont Hospital opens women's urology center

It’s something that women don’t talk about even to their best friends or their doctors. That’s why Beaumont Hospitals has created a new Women’s Urology Center offering leading-edge treatments, innovative research and the most advanced minimally invasive procedures for women’s urological conditions such as incontinence, pelvic pain and sexual dysfunction.

25 Mar 2010

Tips offered in April 2010 issue of American Journal Of Pathology

A group led by Dr. Massimo Loda at the Dana Farber Cancer Institute, Boston, MA has generated a preclinical model of human prostate cancer that mimics the genetic and growth behavior of primary tumors. Their report can be found in the April 2010 issue of the American Journal of Pathology.

25 Mar 2010

ScinoPharm announces record results for fiscal year 2009

ScinoPharm, an active pharmaceutical ingredient specialist, today announced audited record results for its fiscal year 2009. The company posted NT$3.791 billion in revenue, an increase of 20.54% over 2008.

25 Mar 2010

Æterna Zentaris announces 2009 financial and operating results

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported financial and operating results as at and for the fourth quarter and the full year ended December 31, 2009.

24 Mar 2010

RCOG prostate cancer treatment database reaches new milestone

Radiotherapy Centers of Georgia (RCOG), a division of RC Cancer Centers announced today that they have reached a new milestone and recently treated their 12,500th patient for prostate cancer with their ProstRcision® treatment therapy.

24 Mar 2010

Healing Choices study for cancer treatment choice

Recognizing the critically important lapse between the diagnosis and treatment, The Cancer Information Service Research Consortium is conducting a Healing Choices study that will try to determine if receiving a multimedia presentation of medical options helps patients make informed treatment decisions.

24 Mar 2010

Ipsen, GTx expand partnership for toremifene 80 mg

Ipsen today announced the expansion of their partnership for the development and commercialization of toremifene 80 mg for the reduction of fractures in men with advanced prostate cancer on androgen deprivation therapy (ADT) and toremifene 20 mg for the prevention of prostate cancer in high risk patients with High Grade Prostatic Intraepithelial Neoplasia lesions (HGPIN).

23 Mar 2010